Two large phase 3 trials found that oral semaglutide 14 mg did not slow cognitive or functional decline over 104 weeks in ...
A new study suggests that two of Alzheimer’s disease’s most debated players may be more closely connected than they first ...
Hormone therapy is widely used to treat menopausal symptoms such as hot flashes and night sweats. But scientists have long ...
Health and Me on MSN
Weight loss drug semaglutide cannot slow down Alzheimer’s: Lancet study
Evoke and Evoke+ -- the randomized, double-blind, placebo-controlled phase 3 trials conducted across 566 sites in 40 ...
Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...
The results of the EVOKE and EVOKE+ trials were comprehensive in showing oral semaglutide’s lack of clinical efficacy for ...
Eye imaging may help distinguish ALS from Alzheimer’s disease by revealing differences in retinal protein deposits using polarized light.
In TODAY.com's Expert Tip of The Day, a neurologist explains how playing games that build cognitive speed can protect against ...
A study in the journal Neurology has shown that people with type 1 diabetes are three times more likely to develop dementia ...
EatingWell on MSN
You just found out that you’re at risk for dementia—here’s what experts say to do first
Small actions today can help reduce your dementia risk.
GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic ...
New analyses show DLB patients with lower plasma pTau181 levels - indicating an earlier stage of disease and absence of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results